目的: 总结回顾我国药品包装材料（简称药包材）行业的发展过程及监管概况,结合所处环境分析发展趋势,为行业的发展提供参考。方法: 归类我国不同历史时期药包材的产品类型及工业生产特点发展概况,以及与之相适配实施的管理制度,结合行业的发展环境,阐述行业的发展趋势,展望药包材行业面临的挑战与机遇。结果: 我国药包材行业历经70年的发展,特别是近20年的国家层面的监督管理和引导发展,行业由小到大,由弱到强,国民经济行业分类增设“药用辅料及包装材料制造”类别。药包材产品种类由简单到复杂,由单一到多元,产品功能由通用包装储存发展到个性化辅助便利给药,并达到适应经济高速发展和人们生活水平显著提高现状的安全性要求。在国家政策的扶持下,药包材行业展露出智能化、契合药品功能化、绿色化发展的趋势。结论: 我国药包材行业经过70年的发展,从模仿借鉴走向自主研发的道路,已成为我国战略性产业中的重要组成部分,有助于支撑我国医药工业产业的高质量发展。
Objective: To summarize and review the development trajectory and the supervision of China's pharmaceutical packaging industry, analyze the trends in conjunction with the prevailing environment, and to offer insights to inform the industry's growth. Methods: The analysis was anchored in the evolution of product types, the distinctive industrial production features of pharmaceutical packaging materials and the management system adapted across various historical periods in China. It integrated the broader development context of the industry to elucidate current trends and anticipate future challenges and opportunities. Results: Spanning seven decades, China's pharmaceutical packaging industry has experienced significant growth, particularly bolstered by national supervision and guidance over the past twenty years. The industry has transformed from nascent to robust, with the economic sector now formally recognizing "Pharmaceutical Excipients and Packaging Materials Manufacturing". The diversity and complexity of pharmaceutical packaging materials have expanded, evolving from rudimentary to sophisticated and from singular to a multitude of options. Their functionality has advanced from basic containment to personalized, convenient drug delivery solutions, aligning with the rigorous safety demands of a rapidly growing economy and elevated public health standards. Underpinned by state policies, the industry is gravitating towards intelligent, pharmaceutically compatible, and eco-friendly development. Conclusion: After seventy years of evolution, China's pharmaceutical packaging industry has transitioned from a phase of emulation to one of innovation. It has established itself as a vital component of the nation's strategic industries and stands poised to underpin the high-quality development of China's pharmaceutical sector.
[1] 李茂忠,孙会敏,谢兰桂,等. 中国药包材的监管和质量控制[J]. 中国药事,2012,26(2):107-111.
[2] 国家食品药品监督管理局. 直接接触药品的包装材料和容器管理办法(局令第13号)[EB/OL].(2004- 07-20). https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20040720010101543.html.
[3] 国家药品监督管理局. 国家药监局关于进一步完善药品关联审评审批和监管工作有关事宜的公告(2019年第56号)[EB/OL].(2019-07-16). https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20190716174501955.html.
[4] 编者. 突破瓶颈,推动升级—谈我国医药包装产业发展[J]. 中国包装,2022(11):12-13.
[5] 林黄静,田绍琼,梅蕾,等. 药品包装材料的研究进展[J]. 中国医药工业杂志,2023(3):339-346.
[6] 王敏,周苏萍,张帅,等. 注射剂常用包装形式研究使用进展[J]. 药学实践与服务,2023(9):528-533.
[7] 孟伟娟,邱迎昕,齐宇虹,等. 国内外医用溴化丁基橡胶塞产业的发展现状[J]. 橡胶科技,2022(4):161-165.
[8] 贾晶晶,张勇. 从药品包装的变化看我国药包材的发展特点[J]. 临床医学研究与实践,2017,2(5):127-129.
[9] 王瑆. 创新升级推动我国医药包装产业快速发展[J]. 中国包装,2014(1):49-52.
[10] 前瞻产业研究院. 2013年-2017年中国医药包装行业市场前瞻与投资战略规划分析报告[EB/OL].(2024) [2024-09-03]. https://bg.qianzhan.com/report/detail/f8fa2853d9b64c06.html.
[11] 王宗敏,吴晓明,冯国平,等. 试论大容量注射剂包装技术的变革与监管对策[J]. 中国药事,2005,19(7):396-398.
[12] 李新刚,李铮然,赵志刚,等. 对加强药用玻璃包装注射剂药品监管的思考[J]. 药品评价,2013,10(6): 6-8.
[13] 温丽娜. 药品包装为药品安全保驾护航[J]. 印刷技术, 2017(11):15.
[14] 国务院. 国务院关于改革药品医疗器械审评审批制度的意见(国发〔2015〕44号)[EB/OL].(2015-08- 18). https://www.gov.cn/zhengce/content/2015-08/18/content_10101.htm.
[15] 国务院. 关于深化审评审批制度改革鼓励药品医疗器械创新的意见(厅字 [2017] 42号)[EB/OL].(2017- 10-20). https://www.gov.cn/gongbao/content/2017/content_5232362.htm.
[16] 国家药品监督管理局. 国家药监局关于进一步完善药品关联审评审批和监管工作有关事宜的公告(2019年第56号)[EB/OL].(2019-07-16). https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20190716174501955.html.
[17] 王粟明,李崇林,贾颖君,等. 各国关联审评审批制度比对及辅料行业发展思考与对策[J]. 中国食品药品监管,2018(9):24-30.
[18] 蔡弘. 医药包装产业发展与注册制度改革[J]. 中国食品药品监管,2018(9):21-23.
[19] 国家质量监督检验检疫总局,国家标准化管理委员会. 国民经济行业分类(GB/T 4754-2017)[S]. 2017.
[20] Udayakumar GP, Muthusamy S, Selvaganeshb, et al. Biopolymers and Composites: Properties, Characterization and their Applications in Food, Medical and Pharmaceutical Industries[J]. J Environ Chem Eng,2021,9(4):105322.
[21] Mohammadi S, Babaei A.Poly (vinyl alcohol) /Chitosan/ Polyethylene Glycol-Assembled Graphene Oxide Bionanocomposites as a Prosperous Candidate for Biomedical Applications and Drug/Food Packaging Industry[J]. Int J Biol Macromol,2022,201:528-538.
[22] 李秀洁. 环烯烃共聚物助力应对疫苗瓶潜在短缺[J]. 中国石油和化工,2021(2):64-66.
[23] 曲树璋,王伟. 环烯烃共聚物材料应用的研究进展[J]. 石油化工,2022,51(4):477-484.
[24] 张友辉,孙泽讯,周德辉,等. 一种抗菌药品包装复合膜:CN215704780U[P].2022-02-01.
[25] Jildeh NB, Matouq M.Nanotechnology in Packing Materials for Food and Drug Stuff Opportunities[J]. J Environ Chem Eng,2020,8(5):104338.
[26] 袁春平,侯惠民. 生物塑料在食品药品包装中的应用与展望[J]. 中国医药工业杂志,2020,51(11):1356-1363.
[27] 谢彬,白茸茸,孙华山,等. 聚乳酸塑料合成、生物降解及其废弃物处置的研究进展[J]. 生物工程学报, 2023,39(5):1912-1929.
[28] 程一洲,丁茜,吴铫,等. 农作物废弃物制备生物塑料研究进展[J]. 工程塑料应用,2022,50(6):172-176.
[29] 张智超,孙占英,王鑫. 纤维素基生物可降解塑料的研究进展及展望[J]. 工程塑料应用,2022,50(11): 168-172.
[30] 张佳星,王玉增,陈慧,等. 基于动植物蛋白的生物基塑料研究进展[J]. 皮革科学与工程,2021,31(2): 9-15.
[31] 周代芳,熊礼梅. 健康中国建设背景下药品包装的智能化设计[J]. 包装工程,2022,43(2):235-239.
[32] Kumar KA, Gupta NV, Lalasa P, et al.A Review on Packaging Materials with Anti-Counterfeit, Tamper- Evident Features for Pharmaceuticals[J]. Int J Drug Dev Res,2013,5(3):26-34.
[33] 王帅,于萍,范帼玲,等. 智能药品包装材料在多感官维度下的应用研究[J]. 包装工程,2022,43(19): 76-87.
[34] Lotoshynska N, Izonin I, Nazarkevych M, et al.Consumer- Centered Design of the Secondary Packaging for Industrial Pharmaceuticals[J]. CIRP J Manuf Sci Tec,2021,32: 257-265.
[35] 编者. 智能化助推软包装行业升级[J]. 绿色包装,2019 (1):92-93.
[36] Zadbuke N, Shahi S, Gulecha B, et al.Recent Trends and Future of Pharmaceutical Packaging Technology[J]. J Pharm Bioallied Sci,2013,5(2):98-110.
[37] 编者. 传统包装升级为智能包装是必然趋势[J]. 绿色包装,2018(3):85-87.
[38] 编者. 大势所趋:传统包装升级为智能包装[J]. 现代制造,2022(9):41-42.
[39] 编者. 药品种类多元化带来药包材形式多样化[J]. 中国包装,2014(8):58-58.
[40] 吴少祯,严文君,张燕玲,等. 《中国医药产业高质量发展状况调研(2021-2023)》研究报告综述[J]. 中国食品药品监管,2024(3):4-17.
